Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/16882
Tipo
ArtículoDerechos de autor
Acceso abierto
Colecciones
- IOC - Artigos de Periódicos [12642]
Metadatos
Mostrar el registro completo del ítem
ANTIBODY DYNAMICS AND SPONTANEOUS VIRAL CLEARANCE IN PATIENTS WITH ACUTE HEPATITIS C INFECTION IN RIO DE JANEIRO, BRAZIL
Autor
Strasak, Alexander M.
Kim, Arthur Y.
Lauer, Georg M.
Sousa, Paulo S. de
Ginuino, Cleber F.
Fernandes, Carlos A.
Velloso, Carlos E.
Almeida, Adilson J. de
Oliveira, Jaqueline M. de
Yoshida, Clara F.
Schulze zur Wiesch, Julian
Paranhos-Baccalá, Gláucia
Lang, Stefan
Brant, Larry J.
Ulmer, Hanno
Strohmaier, Susanne
Kaltenbach, Lalit
Lampe, Elisabeth
Lewis-Ximenez, Lia L.
Kim, Arthur Y.
Lauer, Georg M.
Sousa, Paulo S. de
Ginuino, Cleber F.
Fernandes, Carlos A.
Velloso, Carlos E.
Almeida, Adilson J. de
Oliveira, Jaqueline M. de
Yoshida, Clara F.
Schulze zur Wiesch, Julian
Paranhos-Baccalá, Gláucia
Lang, Stefan
Brant, Larry J.
Ulmer, Hanno
Strohmaier, Susanne
Kaltenbach, Lalit
Lampe, Elisabeth
Lewis-Ximenez, Lia L.
Afiliación
Innsbruck Medical University. Department of Medical Statistics, Informatics and Health Economics. Innsbruck, Austria.
Harvard Medical School. Boston, MA, USA / Massachussets General Hospital. Division of Infectious Diseases. Boston, MA, USA.
Harvard Medical School. Boston, MA, USA / Massachussets General Hospital. Gastrointestinal Unit. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Laboratório Central de Saúde Pública Noel Nutels. Divisão de Hepatites. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil / Universidade Federal do Estado do Rio de Janeiro. Hospital Universitário Gaffrée Guinle. Unidade de Hepatologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Desenvolvimento Tecnológico em Virologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Universitätsklinikum Eppendorf. Medizinische Klinik I. Hamburg, Germany.
Fondation Merieux. Emerging Pathogens Laboratory. Lyon, France.
University of Innsbruck. Institute of Statistics. Innsbruck, Austria.
National Institute on Aging. Gerontology Research Center. Baltimore, USA.
Innsbruck Medical University. Department of Medical Statistics, Informatics and Health Economics. Innsbruck, Austria.
Innsbruck Medical University. Department of Medical Statistics, Informatics and Health Economics. Innsbruck, Austria.
Innsbruck Medical University. Department of Medical Statistics, Informatics and Health Economics. Innsbruck, Austria.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Harvard Medical School. Boston, MA, USA / Massachussets General Hospital. Division of Infectious Diseases. Boston, MA, USA.
Harvard Medical School. Boston, MA, USA / Massachussets General Hospital. Gastrointestinal Unit. Boston, MA, USA.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Laboratório Central de Saúde Pública Noel Nutels. Divisão de Hepatites. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil / Universidade Federal do Estado do Rio de Janeiro. Hospital Universitário Gaffrée Guinle. Unidade de Hepatologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Desenvolvimento Tecnológico em Virologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Universitätsklinikum Eppendorf. Medizinische Klinik I. Hamburg, Germany.
Fondation Merieux. Emerging Pathogens Laboratory. Lyon, France.
University of Innsbruck. Institute of Statistics. Innsbruck, Austria.
National Institute on Aging. Gerontology Research Center. Baltimore, USA.
Innsbruck Medical University. Department of Medical Statistics, Informatics and Health Economics. Innsbruck, Austria.
Innsbruck Medical University. Department of Medical Statistics, Informatics and Health Economics. Innsbruck, Austria.
Innsbruck Medical University. Department of Medical Statistics, Informatics and Health Economics. Innsbruck, Austria.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hepatites Virais. Rio de Janeiro, RJ. Brasil.
Resumen en ingles
Background: The anti-HCV antibody response has not been well characterized during the early phase of HCV
infection and little is known about its relationship to the clinical course during this period.
Methods: We analyzed serial anti-HCV antibodies longitudinally obtained from a prospective cohort of 65 patients
with acute HCV infection by using a microparticle enzyme immunoassay AxSYM HCV 3.0 (Abbott Diagnostics)
during the first 12 months from HCV acquisition in Rio de Janeiro, Brazil. Spontaneous viral clearance (SVC) was
defined as undetectable HCV RNA in serum, in the absence of treatment, for three consecutive HCV PCR tests
within 12-months of follow-up.
Results: Baseline antibody values were similar among patient groups with self-limiting HCV evolution (n = 34) and
persistent viremia (n = 31) [median (interquartile range) signal/cut-off ratio (s/co) 78.7 (60.7-93.8) vs. 93.9 (67.8-
111.9), p = 0.26]. During 12-months follow-up, patients with acute spontaneous resolving HCV infection showed
significantly lower serial antibody response in comparison to individuals progressing to chronic infection [median
(interquartile range) s/co 62.7 (35.2-85.0) vs. 98.4 (70.4-127.4), p < 0.0001]. In addition, patients with self-limiting HCV
evolution exhibited an expeditious, sharp decline of serial antibody values after SVC in comparison to those
measured before SVC [median (interquartile range) s/co 56.0 (25.4-79.3) vs. 79.4 (66.3-103.0), p < 0.0001].
Conclusion: Our findings indicate a rapid short-term decline of antibody values in patients with acute
spontaneous resolving HCV infection.
Compartir